Thomas Gribbin

6.7k total citations
18 papers, 240 citations indexed

About

Thomas Gribbin is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Thomas Gribbin has authored 18 papers receiving a total of 240 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thomas Gribbin's work include Biochemical and Molecular Research (3 papers), Advanced Breast Cancer Therapies (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Thomas Gribbin is often cited by papers focused on Biochemical and Molecular Research (3 papers), Advanced Breast Cancer Therapies (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Thomas Gribbin collaborates with scholars based in United States, Poland and Switzerland. Thomas Gribbin's co-authors include Jarosław Spychała, Malabika Datta, Irving H. Fox, N S Datta, Beverly S. Mitchell, Jon Oscherwitz, Kemp B. Cease, Jikui Song, S E Walker and Mary E. Zeigler and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Clinical Oncology.

In The Last Decade

Thomas Gribbin

17 papers receiving 234 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Gribbin United States 8 118 59 48 39 38 18 240
Karel P. Alcedo United States 10 185 1.6× 48 0.8× 96 2.0× 53 1.4× 54 1.4× 10 367
Joseph Colofiore United States 13 198 1.7× 152 2.6× 22 0.5× 29 0.7× 32 0.8× 24 329
Caroline Smal Belgium 12 230 1.9× 110 1.9× 48 1.0× 10 0.3× 40 1.1× 22 333
Gannie Tzoneva United States 4 134 1.1× 47 0.8× 35 0.7× 43 1.1× 9 0.2× 8 314
Jason Clark United States 8 165 1.4× 44 0.7× 7 0.1× 43 1.1× 47 1.2× 14 312
Christy M. Gearheart United States 7 194 1.6× 47 0.8× 24 0.5× 51 1.3× 117 3.1× 11 287
Limin Huang China 8 157 1.3× 65 1.1× 7 0.1× 96 2.5× 33 0.9× 22 311
Shaowei Qiu China 10 180 1.5× 71 1.2× 10 0.2× 30 0.8× 37 1.0× 67 344
Kim Rosenthal United States 8 148 1.3× 128 2.2× 71 1.5× 12 0.3× 22 0.6× 10 331
Youwen Qin China 11 197 1.7× 61 1.0× 19 0.4× 64 1.6× 101 2.7× 25 344

Countries citing papers authored by Thomas Gribbin

Since Specialization
Citations

This map shows the geographic impact of Thomas Gribbin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Gribbin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Gribbin more than expected).

Fields of papers citing papers by Thomas Gribbin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Gribbin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Gribbin. The network helps show where Thomas Gribbin may publish in the future.

Co-authorship network of co-authors of Thomas Gribbin

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Gribbin. A scholar is included among the top collaborators of Thomas Gribbin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Gribbin. Thomas Gribbin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Lund, J.C., Kyriakos P. Papadopoulos, Thomas Gribbin, et al.. (2023). Abstract 3855: Establishment and characterization of a panel of breast XPDX models representing innate or acquired resistance to trastuzumab deruxtecan (T-DXd). Cancer Research. 83(7_Supplement). 3855–3855. 1 indexed citations
2.
Lund, J.C., Kyriakos P. Papadopoulos, Gladys Rodriguez, et al.. (2023). Abstract 3869: Short or long-term treatment with CDK4/6 inhibitors in patients with ER+ breast cancer: characterization and comparative analysis of resistance in seventeen XPDX models. Cancer Research. 83(7_Supplement). 3869–3869. 1 indexed citations
3.
Fox, John, Pierre Vanden Borre, Yakov Chudnovsky, et al.. (2019). Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective. Journal of Managed Care & Specialty Pharmacy. 25(5). 601–611. 18 indexed citations
4.
McHugh, Jonathan B., et al.. (2015). Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy. SHILAP Revista de lepidopterología. 2015. 1–4. 2 indexed citations
5.
Picozzi, Vincent J., Ramesh K. Ramanathan, Maeve A. Lowery, et al.. (2014). Feasibility and results of a randomized phase Ιb study of fractionated 90Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies.. Journal of Clinical Oncology. 32(15_suppl). 4026–4026. 8 indexed citations
6.
Sigal, Darren, Stephen Marcus, Peter J. Rosen, et al.. (2013). Association of 2-O, 3-O desulfated heparin (ODSH) plus combination gemcitabine (G)/nab-paclitaxel (A) with preliminary benefit in untreated metastatic pancreatic cancer.. Journal of Clinical Oncology. 31(4_suppl). 284–284. 5 indexed citations
7.
MacKenzie, Shawn, Herbert J. Zeh, Laurence E. McCahill, et al.. (2013). A pilot phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC).. Journal of Clinical Oncology. 31(15_suppl). 4038–4038. 16 indexed citations
8.
Zaren, Howard A., Suresh Nair, Ronald S. Go, et al.. (2013). Early-Phase Clinical Trials In The Community: Results From the National Cancer Institute Community Cancer Centers Program Early-Phase Working Group Baseline Assessment. Journal of Oncology Practice. 9(2). e55–e61. 10 indexed citations
9.
10.
Oscherwitz, Jon, Thomas Gribbin, & Kemp B. Cease. (2010). A CD20 tandem-epitope immunogen elicits antibody in mice that binds murine cell surface CD20 and depletes splenic B cells in vivo☆. Molecular Immunology. 47(7-8). 1484–1491. 6 indexed citations
11.
Möller, Mecker G., et al.. (2006). Breast cancer metastatic to renal cell carcinoma. Surgery. 139(4). 577–579. 10 indexed citations
12.
Oscherwitz, Jon, Mary E. Zeigler, Thomas Gribbin, & Kemp B. Cease. (1999). A V3 loop haptenic peptide sequence, when tandemly repeated, enhances immunogenicity by facilitating helper T-cell responses to a covalently linked carrier protein. Vaccine. 17(19). 2392–2399. 14 indexed citations
13.
Spychała, Jarosław, et al.. (1996). Cloning of human adenosine kinase cDNA: sequence similarity to microbial ribokinases and fructokinases.. Proceedings of the National Academy of Sciences. 93(3). 1232–1237. 101 indexed citations
14.
Song, Jikui, et al.. (1993). Genomic structure and chromosomal localization of the human deoxycytidine kinase gene.. Proceedings of the National Academy of Sciences. 90(2). 431–434. 37 indexed citations
15.
Gribbin, Thomas. (1991). New purine analogues for the treatment of chronic B-cell malignancies.. PubMed. 39(2). 98–102. 2 indexed citations
16.
Gribbin, Thomas, Constance K. Stein, Jonathan S. Harrison, et al.. (1989). Association of a mature B cell leukemia with a 4p+ chromosomal abnormality: derivation and characterization of a cell line.. PubMed. 3(9). 643–7. 5 indexed citations
17.
Gribbin, Thomas, et al.. (1989). Identification of an Apa I polymorphism within the human adenosine deaminase (ADA) gene. Nucleic Acids Research. 17(9). 3626–3626. 1 indexed citations
18.
Gribbin, Thomas, et al.. (1989). Erythrocyte-specific overproduction of adenosine deaminase: molecular genetic studies.. PubMed. 319. 55–64; discussion 65. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karel P. Alcedo Breakdown of academic impact, for papers by Joseph Colofiore Breakdown of academic impact, for papers by Caroline Smal Breakdown of academic impact, for papers by Gannie Tzoneva Breakdown of academic impact, for papers by Jason Clark Breakdown of academic impact, for papers by Christy M. Gearheart Breakdown of academic impact, for papers by Limin Huang Breakdown of academic impact, for papers by Shaowei Qiu Breakdown of academic impact, for papers by Kim Rosenthal Breakdown of academic impact, for papers by Youwen Qin
Rankless by CCL
2026